Colossal Biosciences logo
AIVC-backedSeries C
Dallas, USA · Founded 2021

Colossal Biosciences

Bringing extinct species back to life

Visit colossal.com← Back to Index

About Colossal Biosciences

Colossal Biosciences is using CRISPR gene editing to de-extinct the woolly mammoth, thylacine (Tasmanian tiger), and dodo. Beyond de-extinction, their breakthroughs in gene editing and cold-weather biology create platform technologies for conservation and medicine.

Pitch deck breakdown

How Colossal Biosciences would pitch themselves.

○ Auto-generated
01

Target customer

Companies + developers adopting AI in their stack — from indie builders to enterprise ML teams working on bringing extinct species back to life.

02

Problem they solve

Colossal Biosciences is using CRISPR gene editing to de-extinct the woolly mammoth, thylacine (Tasmanian tiger), and dodo. Beyond de-extinction, their breakthroughs in gene editing and cold-weather biology create platfo… The category has historically been served by tools that miss the modern workflow this product is built around.

03

Key differentiator

Colossal Biosciences differentiates on bringing extinct species back to life. Backed by BOLD Capital + Winklevoss Capital, $225M raised — the company has resources + validation to compound this thesis. Founded by Ben Novak + team.

04

Go-to-market strategy

Growth-stage GTM — multi-channel revenue motion (direct enterprise sales, channel partnerships, marketplace listings). Vertical specialisation + verticalised AE teams targeting enterprise + mid-market.

Founder of Colossal Biosciences? Submit your own pitch breakdown to replace this auto-generated overview.
Submit pitch →

Colossal Biosciences website preview

Screenshot of Colossal Biosciences (colossal.com) — Bringing extinct species back to life

Company facts

Category
AI
Funding stage
Series C
Total raised
$225M
Founded
2021
Team size
50-200
HQ
Dallas
Country
USA
Website
colossal.com

Founders of Colossal Biosciences

  • Ben Novak
  • George Church

Investors backing Colossal Biosciences

  • BOLD Capital
  • Winklevoss Capital

Frequently asked questions

What does Colossal Biosciences do?

Colossal Biosciences is using CRISPR gene editing to de-extinct the woolly mammoth, thylacine (Tasmanian tiger), and dodo. Beyond de-extinction, their breakthroughs in gene editing and cold-weather biology create platform technologies for conservation and medicine.

Where is Colossal Biosciences based?

Colossal Biosciences is based in Dallas, USA.

When was Colossal Biosciences founded?

Colossal Biosciences was founded in 2021.

How much has Colossal Biosciences raised?

Colossal Biosciences has raised $225M in their Series C round.

Who founded Colossal Biosciences?

Colossal Biosciences was founded by Ben Novak, George Church.

Who has invested in Colossal Biosciences?

Colossal Biosciences is backed by BOLD Capital, Winklevoss Capital.

More AI startups